PepsCompare peptide research
Put two or three profiles side by side to compare identities, mechanisms, study populations, findings, and uncertainty.
This compares research contexts. It does not rank treatments, recommend combinations, or assume that results from different trials are directly comparable.
Permanent link to this selection ↗| Research question | BPC-157 Research topics | TB-500 Research topics |
|---|---|---|
| Identity | Experimental pentadecapeptide | Thymosin beta-4-related fragment |
| Research area | Experimental tissue-repair research | Thymosin-fragment research |
| Context | BPC-157 is a 15-amino-acid research peptide. Selected animal injury studies and a two-person human safety pilot explore different questions; neither establishes treatment benefit for injured patients. | TB-500 is associated with a short thymosin beta-4 fragment. Much of the biology cited in marketing instead concerns the full-length parent peptide. |
| Mechanism | One proposed pathway involves changing growth-hormone receptor expression in tendon fibroblasts. This offers a cellular hypothesis for repair research without establishing how an injured human tendon responds. | Thymosin beta-4 research examines actin-related processes, cell migration, and wound responses. Different regions can have different activities; a short sequence does not inherit all parent-protein effects. |
| Selected evidence | Growth-hormone receptor experiment Achilles tendon transection model Medial collateral ligament healing BPC-157 · two-person safety pilot | Thymosin beta-4 active regions RGN-259 in severe dry eye — related molecule |
| Findings & limits | Growth-hormone receptor experiment A change in isolated cells is a possible mechanism, not a measured improvement in human tendon strength, pain, return to sport, or long-term safety. Achilles tendon transection model An acute surgical injury in rats differs from human tendinopathy or rehabilitation. These findings do not establish a human recovery time, effective clinical treatment, or long-term safety. Medial collateral ligament healing This remains animal evidence. Several routes studied in a model do not establish equivalent exposure, benefit, or safety in people. BPC-157 · two-person safety pilot The study cannot detect uncommon or delayed harms, establish injury-healing efficacy, or validate research-use products. The authors’ broad safety conclusion exceeds what this design can establish. Larger controlled studies and pharmaceutical-quality identity checks remain necessary. | Thymosin beta-4 active regions This is background on related sequences, not direct clinical evidence for a marketed TB-500 preparation. It must not be presented as a human recovery trial. RGN-259 in severe dry eye — related molecule A very small trial with multiple assessments. It does not test a TB-500 fragment, systemic administration, tendon repair, or a seller’s vial. Related-compound evidence must not be presented as a TB-500 clinical trial. |
| Status & use context | This profile covers experimental tissue biology. The linked experiment does not provide an established clinical use, recovery timetable, or validated combination with TB-500. Human clinical claims need their own controlled evidence. | The linked mechanistic paper is related background, not a clinical TB-500 efficacy trial. FDA identifies the LKKTETQ fragment under this name. Exact sequence and modification must be checked before associating a study with a listing. |
| Safety context | FDA flags limited safety information. The tendon-cell paper cannot measure systemic adverse effects, immune reactions, or long-term risks. A vendor purity result would answer a different question from clinical safety. Safety source ↗The recent pilot monitored only two previously exposed adults for three days. It cannot exclude delayed or uncommon harms and did not test injury-healing benefit. Safety source ↗ | FDA identifies a human-exposure data gap. Evidence about a parent protein cannot establish fragment or commercial-preparation safety. Safety source ↗ |
| Product distinction | A tendon-cell experiment cannot establish recovery time, pain relief, or a reliable injury treatment in people. | FDA identifies a thymosin beta-4 fragment under this name. Findings about full-length thymosin beta-4 do not automatically transfer. |
| Continue researching |
PepsRadar editorial summaries · Not reviewed by a medical professional · Selected coverage, not a systematic review. Source-check dates do not mean continuous monitoring.